S&P 500   4,301.89 (+0.19%)
DOW   33,844.68 (+0.03%)
QQQ   354.28 (+0.32%)
AAPL   181.40 (+0.46%)
MSFT   326.82 (+0.48%)
META   264.87 (+0.11%)
GOOGL   122.43 (+0.24%)
AMZN   123.71 (-0.43%)
TSLA   245.73 (+4.63%)
NVDA   388.85 (+0.97%)
NIO   7.85 (+0.77%)
BABA   85.84 (-0.35%)
AMD   124.23 (+2.63%)
T   16.02 (-0.31%)
F   13.83 (+1.84%)
MU   65.08 (-0.37%)
CGC   0.67 (-3.20%)
GE   105.22 (-0.80%)
DIS   91.83 (-0.76%)
AMC   4.74 (+1.28%)
PFE   38.97 (-0.31%)
PYPL   63.26 (-1.53%)
NFLX   423.71 (+3.50%)
S&P 500   4,301.89 (+0.19%)
DOW   33,844.68 (+0.03%)
QQQ   354.28 (+0.32%)
AAPL   181.40 (+0.46%)
MSFT   326.82 (+0.48%)
META   264.87 (+0.11%)
GOOGL   122.43 (+0.24%)
AMZN   123.71 (-0.43%)
TSLA   245.73 (+4.63%)
NVDA   388.85 (+0.97%)
NIO   7.85 (+0.77%)
BABA   85.84 (-0.35%)
AMD   124.23 (+2.63%)
T   16.02 (-0.31%)
F   13.83 (+1.84%)
MU   65.08 (-0.37%)
CGC   0.67 (-3.20%)
GE   105.22 (-0.80%)
DIS   91.83 (-0.76%)
AMC   4.74 (+1.28%)
PFE   38.97 (-0.31%)
PYPL   63.26 (-1.53%)
NFLX   423.71 (+3.50%)
S&P 500   4,301.89 (+0.19%)
DOW   33,844.68 (+0.03%)
QQQ   354.28 (+0.32%)
AAPL   181.40 (+0.46%)
MSFT   326.82 (+0.48%)
META   264.87 (+0.11%)
GOOGL   122.43 (+0.24%)
AMZN   123.71 (-0.43%)
TSLA   245.73 (+4.63%)
NVDA   388.85 (+0.97%)
NIO   7.85 (+0.77%)
BABA   85.84 (-0.35%)
AMD   124.23 (+2.63%)
T   16.02 (-0.31%)
F   13.83 (+1.84%)
MU   65.08 (-0.37%)
CGC   0.67 (-3.20%)
GE   105.22 (-0.80%)
DIS   91.83 (-0.76%)
AMC   4.74 (+1.28%)
PFE   38.97 (-0.31%)
PYPL   63.26 (-1.53%)
NFLX   423.71 (+3.50%)
S&P 500   4,301.89 (+0.19%)
DOW   33,844.68 (+0.03%)
QQQ   354.28 (+0.32%)
AAPL   181.40 (+0.46%)
MSFT   326.82 (+0.48%)
META   264.87 (+0.11%)
GOOGL   122.43 (+0.24%)
AMZN   123.71 (-0.43%)
TSLA   245.73 (+4.63%)
NVDA   388.85 (+0.97%)
NIO   7.85 (+0.77%)
BABA   85.84 (-0.35%)
AMD   124.23 (+2.63%)
T   16.02 (-0.31%)
F   13.83 (+1.84%)
MU   65.08 (-0.37%)
CGC   0.67 (-3.20%)
GE   105.22 (-0.80%)
DIS   91.83 (-0.76%)
AMC   4.74 (+1.28%)
PFE   38.97 (-0.31%)
PYPL   63.26 (-1.53%)
NFLX   423.71 (+3.50%)
OTCMKTS:DSRLF

DiaSorin (DSRLF) Stock Forecast, Price & News

$104.50
0.00 (0.00%)
(As of 06/8/2023 ET)
Compare
Today's Range
$104.50
▼
$104.50
50-Day Range
$104.50
▼
$120.00
52-Week Range
$104.50
▼
$147.15
Volume
N/A
Average Volume
1 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$143.00
ProfileAnalyst RatingsChartCompetitorsHeadlinesShort Interest

DSRLF stock logo

About DiaSorin (OTCMKTS:DSRLF) Stock

DiaSorin SpA engages in developing, producing and marketing reagent kits for laboratory diagnostics. The firm specializes in the immunodiagnostics and molecular diagnostics segments. It provides clinical services in the areas like Infectious Diseases, Bone and Mineral, Endocrinology, Hypertension, Oncology, Stool Diagnostics and Autoimmunity. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Receive DSRLF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DiaSorin and its competitors with MarketBeat's FREE daily newsletter.

DSRLF Stock News Headlines

May 28, 2023 | americanbankingnews.com
DiaSorin S.p.A. (OTCMKTS:DSRLF) Given Consensus Recommendation of "Reduce" by Brokerages
May 9, 2023 | msn.com
DiaSorin confirms 2023 guidance after Q1 results
June 9, 2023 | Edge On The Street (Ad)
Graphite versus Lithium - What Investors Should Know
Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.
May 1, 2023 | americanbankingnews.com
Brokerages Set DiaSorin S.p.A. (OTCMKTS:DSRLF) PT at $144.00
April 15, 2023 | americanbankingnews.com
DiaSorin (OTCMKTS:DSRLF) vs. Bankinter (OTCMKTS:BKNIY) Head to Head Survey
April 8, 2023 | americanbankingnews.com
Brokerages Set DiaSorin S.p.A. (OTCMKTS:DSRLF) Price Target at $144.00
April 6, 2023 | barrons.com
DiaSorin S.p.A.
April 6, 2023 | americanbankingnews.com
DiaSorin (OTCMKTS:DSRLF) Downgraded by Kepler Capital Markets
June 9, 2023 | PressReach (Ad)
This Stock's Worth Researching
Uncover the buzz behind this trending stock. Read the comprehensive report here.
April 4, 2023 | americanbankingnews.com
DiaSorin S.p.A. (OTCMKTS:DSRLF) Sees Significant Growth in Short Interest
April 1, 2023 | americanbankingnews.com
DiaSorin S.p.A. (OTCMKTS:DSRLF) Expected to Earn Q1 2023 Earnings of $1.00 Per Share
March 31, 2023 | americanbankingnews.com
DiaSorin S.p.A. (OTCMKTS:DSRLF) Forecasted to Earn FY2023 Earnings of $4.13 Per Share
March 29, 2023 | seekingalpha.com
DiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call Transcript
March 4, 2023 | seekingalpha.com
DiaSorin: Overvalued Italian Healthcare Company
February 15, 2023 | wsj.com
Cytek(R) Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
February 13, 2023 | finance.yahoo.com
Cytek® Biosciences to Acquire Flow Cytometry and Imaging Business from DiaSorin
October 31, 2022 | reuters.com
DIAS.MI - DiaSorin SpA | Stock Price & Latest News | Reuters
August 8, 2022 | seekingalpha.com
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call Transcript
October 23, 2021 | finance.yahoo.com
Southwest Airlines Company (LUV) stock forecast and price target
August 2, 2021 | seekingalpha.com
DiaSorin S.p.A. 2021 Q2 - Results - Earnings Call Presentation
April 21, 2021 | businesswire.com
QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early ...
April 13, 2021 | finance.yahoo.com
Luminex (LMNX) to Get Acquired by DiaSorin for Around $1.8B
April 12, 2021 | finance.yahoo.com
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Luminex Corporation Buyout
April 12, 2021 | markets.businessinsider.com
DiaSorin To Buy Luminex For $1.8 Bln
April 12, 2021 | finance.yahoo.com
Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction with DiaSorin
April 12, 2021 | investing.com
Luminex Jumps on $1.8 Billion Deal from Italy’s DiaSorin
April 12, 2021 | msn.com
Luminex Jumps on $1.8 Billion Pact to Be Bought by DiaSorin
See More Headlines

DSRLF Price History

DSRLF Company Calendar

Today
6/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:DSRLF
CUSIP
N/A
CIK
N/A
Web
www.diasoringroup.com
Phone
391614871
Fax
N/A
Employees
3,358
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$143.00
High Stock Price Forecast
$153.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+36.8%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.46 billion
Price / Sales
N/A
Cash Flow
$9.79 per share
Price / Cash Flow
10.67
Book Value
$29.58 per share
Price / Book
3.53

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
0.45

Key Executives

  • Carlo Rosa
    Chief Executive Officer, Executive Director & GM
  • Riccardo Palmisano
    CEO
  • Piergiorgio Pedron
    Group Chief Financial Officer & Senior VP
  • Chen Menachem Even
    Executive Director & Chief Commercial Officer
  • Riccardo Fava
    Vice President-Investor Relations & Communications

Key Competitors

View All Competitors













DSRLF Stock - Frequently Asked Questions

Should I buy or sell DiaSorin stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaSorin in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" DSRLF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DSRLF, but not buy additional shares or sell existing shares.
View DSRLF analyst ratings or view top-rated stocks.

What is DiaSorin's stock price forecast for 2023?

6 brokerages have issued 12-month target prices for DiaSorin's shares. Their DSRLF share price forecasts range from $135.00 to $153.00. On average, they anticipate the company's share price to reach $143.00 in the next twelve months. This suggests a possible upside of 36.8% from the stock's current price.
View analysts price targets for DSRLF or view top-rated stocks among Wall Street analysts.

How have DSRLF shares performed in 2023?

DiaSorin's stock was trading at $147.15 at the beginning of 2023. Since then, DSRLF stock has decreased by 29.0% and is now trading at $104.50.
View the best growth stocks for 2023 here.

Are investors shorting DiaSorin?

DiaSorin saw a increase in short interest in May. As of May 15th, there was short interest totaling 285,000 shares, an increase of 28.8% from the April 30th total of 221,300 shares. Based on an average daily volume of 100 shares, the short-interest ratio is currently 2,850.0 days.
View DiaSorin's Short Interest.

What is DiaSorin's stock symbol?

DiaSorin trades on the OTCMKTS under the ticker symbol "DSRLF."

How do I buy shares of DiaSorin?

Shares of DSRLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DiaSorin's stock price today?

One share of DSRLF stock can currently be purchased for approximately $104.50.

How many employees does DiaSorin have?

The company employs 3,358 workers across the globe.

How can I contact DiaSorin?

DiaSorin's mailing address is Via Crescentino, Saluggia L6, 13040. The official website for the company is www.diasoringroup.com. The company can be reached via phone at 391614871 or via email at ines.diterlizzi@diasorin.it.

This page (OTCMKTS:DSRLF) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -